Shares of Moderna jumped 2.93% to $127.70 at 13:54 EST on Thursday, following last session’s downward trend. NASDAQ Composite is rising 0.25% to $13,162.34, after two consecutive sessions in a row of gains. This seems, so far, a somewhat positive trend trading session today.

Moderna’s last close was $124.06, 39.78% below its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1986.4% for the current quarter and 19117.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 18.9% and 660%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.


Moderna’s last day, last week, and last month’s average volatility was a negative 0.39%, a positive 1.35%, and a negative 1.17%, respectively.

Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 5.67%, 7.02%, and 8.45%, respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $127.70 at 13:54 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.91.

Moderna’s Moving Average

Moderna’s worth is below its 50-day moving average of $133.18 and way above its 200-day moving average of $86.91.

Previous days news about Moderna

Moderna provides business update and announces three new development programs in infectious disease vaccines. According to Business Insider on Monday, 11 January, "Prophylactic Vaccines: Moderna is developing vaccines against viral diseases where there is unmet medical need – including complex vaccines with multiple antigens for common diseases, as well as vaccines against threats to global public health. ", "Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. "

Moderna to develop vaccine candidates for seasonal flu, HIV. According to MarketWatch on Monday, 11 January, "This follows the success of its mRNA COVID-19 vaccine, which is one of two vaccines to be authorized so far in the U.S. CEO Moderna also said it plans to expand its respiratory syncytial virus to include older adults, and it plans to test different vaccine combinations that fight the flu, COVID-19, RSV, and human metapneumovirus. ", " As part of its corporate update, Moderna said it had about $5.2 billion in cash as of Dec. 31, compared to the $1.2 billion in cash it had at the same time a year ago, and it expects to generate at least $11.7 billion in revenue in 2021 for its COVID-19 vaccine based on advance purchase agreements. "

Uber and Moderna team up to boost vaccine awareness. According to Bloomberg Quint on Tuesday, 12 January, "Uber and Moderna said the effort may also include working with public health officials to build ride-scheduling into the booking process and send text reminders for appointments. ", "The company is partnering with Covid-19 vaccine developer Moderna Inc. to provide vaccine information, and eventually even help schedule rides to appointments."

Uber, Moderna to collaborate on supporting Covid-19 vaccine uptake. According to MarketWatch on Tuesday, 12 January, "Uber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. "

Beacon christian community health shows how it's done with its successful Moderna Covid-19 vaccination program. According to Business Insider on Wednesday, 13 January, "Dr. Janet Kim, Chief Medical Officer, Beacon Health, continued, "We took one of our two Staten Island facilities, configured and staffed it solely for COVID-19 testing and Moderna COVID-19 Vaccine inoculations. ", "Beacon Christian Community Health Center, Inc. announced that it had administered more than 100% of its allocation of the Moderna COVID-19 Vaccine inoculations in compliance with NY State’s Vaccinate New York Phase 1A eligibility requirements and Governor Cuomo’s timeline directives. "


Please enter your comment!
Please enter your name here